Literature DB >> 23489072

Loss of constitutive activity is correlated with increased thermostability of the human adenosine A2A receptor.

Nicolas Bertheleme1, Shweta Singh, Simon J Dowell, Julia Hubbard, Bernadette Byrne.   

Abstract

BACKGROUND AND
PURPOSE: Thermostabilization by mutagenesis is one method which has facilitated the determination of high-resolution structures of the adenosine A2A receptor (A(2A)R). Sets of mutations were identified, which both thermostabilized the receptor and resulted in preferential agonist (Rag23 mutant) or antagonist (Rant5 and Rant21) binding forms as assessed by radioligand binding analysis. While the ligand-binding profiles of these mutants are known, the effects these mutations have on receptor activation and downstream signalling are less well characterized. EXPERIMENTAL APPROACH: Here we have investigated the effects of the thermostabilizing mutations on receptor activation using a yeast cell growth assay. The assay employs an engineered Saccharomyces cerevisiae, MMY24, which couples receptor activation to cell growth. KEY
RESULTS: Analysis of the receptor activation profile revealed that the wild-type (WT) A(2A)R had considerable constitutive activity. In contrast, the Rag23, Rant5 and Rant21 thermostabilized mutants all exhibited no constitutive activity. While the preferentially antagonist-binding mutants Rant5 and Rant21 showed a complete lack of agonist-induced activity, the Rag23 mutant showed high levels of agonist-induced receptor activity. Further analysis using a mutant intermediate between Rag23 and WT indicated that the loss of constitutive activity observed in the agonist responsive mutants was not due to reduced G-protein coupling. CONCLUSIONS AND IMPLICATIONS: The loss of constitutive activity may be an important feature of these thermostabilized GPCRs. In addition, the constitutively active and agonist-induced active conformations of the A(2A)R are distinct.
© 2013 The Authors. British Journal of Pharmacology © 2013 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23489072      PMCID: PMC3696323          DOI: 10.1111/bph.12165

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

Review 1.  Mechanisms of inverse agonism at G-protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Trends Pharmacol Sci       Date:  2002-02       Impact factor: 14.819

2.  Transferability of thermostabilizing mutations between beta-adrenergic receptors.

Authors:  Maria J Serrano-Vega; Christopher G Tate
Journal:  Mol Membr Biol       Date:  2009-12       Impact factor: 2.857

3.  [(3)H]ZM241385--an antagonist radioligand for adenosine A(2A) receptors in rat brain.

Authors:  S P Alexander; P J Millns
Journal:  Eur J Pharmacol       Date:  2001-01-12       Impact factor: 4.432

4.  A constitutively active G-protein-coupled receptor causes mating self-compatibility in the mushroom Coprinus.

Authors:  N S Olesnicky; A J Brown; S J Dowell; L A Casselton
Journal:  EMBO J       Date:  1999-05-17       Impact factor: 11.598

5.  Removal of the carboxy terminus of the A2A-adenosine receptor blunts constitutive activity: differential effect on cAMP accumulation and MAP kinase stimulation.

Authors:  Markus Klinger; Mandy Kuhn; Herwig Just; Eduard Stefan; Timothy Palmer; Michael Freissmuth; Christian Nanoff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-08-28       Impact factor: 3.000

6.  The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.

Authors:  Veli-Pekka Jaakola; Mark T Griffith; Michael A Hanson; Vadim Cherezov; Ellen Y T Chien; J Robert Lane; Adriaan P Ijzerman; Raymond C Stevens
Journal:  Science       Date:  2008-10-02       Impact factor: 47.728

7.  Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors.

Authors:  Lucie P Pellissier; Jessica Sallander; Mercedes Campillo; Florence Gaven; Emilie Queffeulou; Marion Pillot; Aline Dumuis; Sylvie Claeysen; Joël Bockaert; Leonardo Pardo
Journal:  Mol Pharmacol       Date:  2009-01-23       Impact factor: 4.436

8.  Conformational thermostabilization of the beta1-adrenergic receptor in a detergent-resistant form.

Authors:  Maria J Serrano-Vega; Francesca Magnani; Yoko Shibata; Christopher G Tate
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-11       Impact factor: 11.205

9.  Structure of the δ-opioid receptor bound to naltrindole.

Authors:  Sébastien Granier; Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; William I Weis; Brian K Kobilka
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

10.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.

Authors:  Guillaume Lebon; Tony Warne; Patricia C Edwards; Kirstie Bennett; Christopher J Langmead; Andrew G W Leslie; Christopher G Tate
Journal:  Nature       Date:  2011-05-18       Impact factor: 49.962

View more
  12 in total

1.  A methodology for creating mutants of G-protein coupled receptors stabilized in active state by combining statistical thermodynamics and evolutionary molecular engineering.

Authors:  Taisei Yamamoto; Satoshi Yasuda; Rinshi S Kasai; Ryosuke Nakano; Simon Hikiri; Kanna Sugaya; Tomohiko Hayashi; Satoshi Ogasawara; Mitsunori Shiroishi; Takahiro K Fujiwara; Masahiro Kinoshita; Takeshi Murata
Journal:  Protein Sci       Date:  2022-10       Impact factor: 6.993

2.  Characterization of binding kinetics of A2AR to Gαs protein by surface plasmon resonance.

Authors:  Kirsten S Koretz; Claire E McGraw; Steven Stradley; Ahmed Elbaradei; Noah Malmstadt; Anne S Robinson
Journal:  Biophys J       Date:  2021-03-04       Impact factor: 4.033

3.  Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast.

Authors:  C Weston; D Poyner; V Patel; S Dowell; G Ladds
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

4.  Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2).

Authors:  Cathryn Weston; Jing Lu; Naichang Li; Kerry Barkan; Gareth O Richards; David J Roberts; Timothy M Skerry; David Poyner; Meenakshi Pardamwar; Christopher A Reynolds; Simon J Dowell; Gary B Willars; Graham Ladds
Journal:  J Biol Chem       Date:  2015-07-21       Impact factor: 5.157

5.  Ligand modulation of sidechain dynamics in a wild-type human GPCR.

Authors:  Lindsay D Clark; Igor Dikiy; Karen Chapman; Karin Ej Rödström; James Aramini; Michael V LeVine; George Khelashvili; Søren Gf Rasmussen; Kevin H Gardner; Daniel M Rosenbaum
Journal:  Elife       Date:  2017-10-06       Impact factor: 8.140

6.  Functional Expression of Adenosine A3 Receptor in Yeast Utilizing a Chimera with the A2AR C-Terminus.

Authors:  Abhinav R Jain; Anne S Robinson
Journal:  Int J Mol Sci       Date:  2020-06-26       Impact factor: 5.923

7.  Ligand-induced conformational changes in a SMALP-encapsulated GPCR.

Authors:  Sarah J Routledge; Mohammed Jamshad; Haydn A Little; Yu-Pin Lin; John Simms; Alpesh Thakker; Corinne M Spickett; Roslyn M Bill; Tim R Dafforn; David R Poyner; Mark Wheatley
Journal:  Biochim Biophys Acta Biomembr       Date:  2020-02-29       Impact factor: 3.747

8.  Bridging non-overlapping reads illuminates high-order epistasis between distal protein sites in a GPCR.

Authors:  Justin I Yoo; Patrick S Daugherty; Michelle A O'Malley
Journal:  Nat Commun       Date:  2020-02-04       Impact factor: 14.919

9.  Pharmacological properties of acid N-thiazolylamide FFA2 agonists.

Authors:  Andrew J Brown; Christina Tsoulou; Emma Ward; Elaine Gower; Nisha Bhudia; Forhad Chowdhury; Tony W Dean; Nicolas Faucher; Akanksha Gangar; Simon J Dowell
Journal:  Pharmacol Res Perspect       Date:  2015-05-08

10.  Arginine 199 and leucine 208 have key roles in the control of adenosine A2A receptor signalling function.

Authors:  Nicolas Bertheleme; Annette Strege; Sorrel E Bunting; Simon J Dowell; Bernadette Byrne
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.